SuperworthCalciMedica price to book ratio CALC
Market value divided by the book value of the company's net assets, since 2023.
- Today, Oct 23, 2026
- 1.5×
- 3-year median
- 2.7×
- Against its 3-year history
- 20th
- percentile: 0 is its lowest day, 100 its highest
- 3-year range
- 0.7× to 7.6×
- Peer median
- 1.6×
CalciMedica's price to book ratio is 1.5× as of Oct 23, 2026.
That is below its 3-year median of 2.7×, lower than on 80% of days in the last 3 years.
Over that time it ranged from 0.7× in Oct 2023 to 7.6× in May 2024.
The median for 3 large drugmakers of a similar size is 1.6×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 1.5× | 1.3× | 4.2× |
| 2025 | 7.0× | 1.4× | 7.3× |
| 2024 | 4.3× | 1.6× | 7.6× |
| 2023 | 1.3× | 0.7× | 1.8× |
Against its peers
Companies in Drug Manufacturers - General nearest CalciMedica's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| CALCCalciMedica | 1.5× |
| ATNMActinium Pharmaceuticals | 1.6× |
| SPROSpero Therapeutics | 1.5× |
| LFVNLifevantage | 2.2× |
| Peer median | 1.6× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on CalciMedica
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.